CARDOZA GEORGE purchased $141K of SOPH
CARDOZA GEORGE (Chief Financial Officer) purchased 20,000 shares of SOPHiA GENETICS SA (SOPH) at $7.06 ($0.14M total) on 2026-11-06.
How this was made
The 30-second read
Why it matters
The CFO's purchase adds a modest amount of shares to his stake, potentially signaling confidence but unlikely to move the stock significantly.
Market read
A small insider purchase that may generate slight positive sentiment but has limited trading relevance.
What to watch
The CFO's buy could be driven by personal tax planning rather than confidence in the business.
Background
SEC Form 4 filings disclose insider transactions and are primary sources for corporate insider activity.
Ticker impact
CFO Cardoza George bought 20,000 SOPH shares for $141,200 on 2026-11-06, raising his holding to 326,726 shares.
likely modest upward pressure as investors interpret the CFO's buy as a positive signal
The transaction size is small relative to market cap, but insider buying is generally viewed favorably.
Market effects
Minimal impact on the broader biotech sector; insider activity is company‑specific.
No discernible regional effect; the filing is a routine U.S. SEC disclosure.
Limited global relevance; only investors in SOPH may adjust positions.
Counterpoint
The purchase may be routine portfolio rebalancing and not a strong endorsement of future performance.
Key entities
- companySOPHiA GENETICS SA
Swiss biotech firm listed on NASDAQ under the ticker SOPH.
- personCardoza George
Chief Financial Officer of SOPHiA GENETICS SA.



